化学信息：

中文名	五味子酯甲
英文名	Schisantherin A
中文别名	-
英文别名	Gomisin C; Schisantherin A; Wuweizi ester A
来源	华中五味子Schisandra sphenanthera Rehd. et Wils.
化合物类型	苯丙素类(Phenylpropanoids)>木脂素>联苯环辛烯类
化学式	C30H32O9
分子量	536.57
CAS号	58546-56-8
纯度	98%, HPLC
溶剂/溶解度	DMSO: ≥ 100 mg/ml (186.37 mM); Water: < 0.1 mg/ml (insoluble)
溶液配制	10mg加入1.86ml DMSO，或者每5.37mg加入1ml DMSO，配制成10mM溶液。

生物信息

产品描述	Schisantherin A is a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera. Schisantherin A inhibits p65-NF-κB translocation into the nucleus by IκBα degradation.
信号通路	-
靶点	IκBα	TNF-α	IL-6	NO	PGE2
IC50	-	2.5 or 25 mg/l	2.5 or 25 mg/l	-	-
体外研究	The concentrations of TNF-α and IL-6 in the supernatant of cells pretreated with 2.5 or 25 mg/L of Schisantherin A are significantly decreased compared to the LPS control group (p<0.05, p<0.01). The potential cytotoxicity of Schisantherin A is evaluated by the MTT assay after incubating cells for 24 h in the absence or presence of LPS, result shows cell viabilities are not affected by the cytokines at concentrations used (0.5, 2.5, 25 mg/L). RAW 264.7 murine macrophage cells are pre-incubated with Schisantherin A for 1 h and then stimulated with 1 mg/L LPS for 12 h. Both LPS and samples are untreated in control group. After the cell culture media are collected, nitrite and PGE2 levels are determined, and Schisantherin A is found to reduce NO and PGE2 production in a dose-dependent manner.
体内研究	Schisantherin A, a dibenzocyclooctadiene lignan isolated from the fruit of Schisandra sphenanthera, has been reported to possess varied beneficial pharmacological effects. Schisantherin A protects lipopolysaccharide-induced acute respiratory distress syndrome in mice through inhibiting NF-κB and MAPKs signaling pathways. Pretreatment with Schisantherin A markedly ameliorates LPS-induced histopathologic changes and decreases the levels of TNF-α, IL-6 and IL-1β in the BALF. In addition, the phosphorylation of NF-κB p65, IκB-α, JNK, ERK and p38 induced by LPS are suppressed by Schisantherin A. The lung wet/dry weight ratio is evaluated at 7 h after the intranasal instillation of LPS. The results show that there are no differences between control group and Schisantherin A (40 mg/kg) group (p>0.05). LPS causes a significant increase in lung wet/dry weight ratio (p<0.01) compared with the control group. Schisantherin A dose-dependently decreases the lung wet/dry weight ratio (p<0.05) compared to those in the LPS group.
临床实验	N/A

参考文献：

1.Ci X, et al. Inflammation. 2010,33(2):126-36.

2.Zhou E, et al. Int Immunopharmacol. 2014,22(1):133-40.

包装清单：

产品编号	产品名称	包装
SM1088-10mM	五味子酯甲(98%, HPLC)	10mM×0.2ml
SM1088-25mg	五味子酯甲(98%, HPLC)	25mg
SM1088-100mg	五味子酯甲(98%, HPLC)	100mg
－	说明书	1份

保存条件：

-20℃保存，至少一年有效。固体粉末4℃保存，至少一个月有效。如果溶于非DMSO溶剂，建议分装后-80℃保存，预计6个月内有效。

注意事项：

本产品可能对人体有一定的毒害作用，请注意适当防护，以避免直接接触人体或吸入体内。

本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。

为了您的安全和健康，请穿实验服并戴一次性手套操作。

使用说明：
1.收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒，以使液体或粉末充分沉降至管底后再开盖使用。
2.对于10mM溶液，可直接稀释使用。对于固体，请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
3.具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献，或者根据实验目的，以及所培养的特定细胞和组织，通过实验进行摸索和优化。
4.不同实验动物依据体表面积的等效剂量转换表请参考如下网页：
https://www.beyotime.com/support/animal-dose.htm